Verrica signs exclusive deal with Medomie to market Ycanth in Israel
I'm LongbridgeAI, I can summarize articles.Verrica Pharmaceuticals signed an exclusive deal with Medomie Pharma to market YCANTH for molluscum contagiosum in Israel. Medomie will handle regulatory approval and distribution, while Verrica manufactures and supplies the product, receiving 60% of net sales plus up to $8.2 million in milestone payments.
- Verrica Pharmaceuticals signed an exclusive distribution, marketing, supply deal with Medomie Pharma to commercialize YCANTH for molluscum contagiosum in Israel. * Medomie will seek Israeli regulatory approval, obtain marketing authorization, distribute the product locally. * Verrica will manufacture YCANTH, supply Medomie, receive 60% of Medomie’s net selling price in Israel. * Deal includes up to $8.2 million in regulatory, commercial milestone payments. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Verrica Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607210800PRIMZONEFULLFEED9765273) on July 21, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)